Analysis of 3,294 cases of upper gastrointestinal bleeding in military medical facilities.
American Journal of Gastroenterology 1995 April
OBJECTIVES: Upper gastrointestinal bleeding (UGIB) remains a commonly encountered medical emergency with significant morbidity and mortality. Most large studies detailing the specific incidence, demographic, and mortality data were performed more than a decade ago. This study analyzes 3,294 cases of UGIB from 139 military medical treatment facilities over a 12-month period.
METHODS: A retrospective chart review of Department of Defense military medical treatment facilities for UGIB was performed from October 1990 through September 1991. Core data such as demographic information were analyzed, as well as specific data relating to UGIB.
RESULTS: The incidence of UGIB was 36 per 100,000 population with a male-to-female ratio of 2.18 and a mean age of 52 +/- 19.65 yr. The number of cases increased with age; 44.5% of all patients were > or = 60 yr old. The overall mortality was 7.0% (231 of 3294), and death rates were similar among males and females (7.1% vs. 6.8%) with an odds ratio of 1.03 (CI: 0.77-1.402). Mortality increased with age in both genders; 73.2% of deaths occurred in patients more than 60 yr old. Comorbid illness was noted in 50.9% (1675 of 3294) of patients, with similar occurrence in males (48.7%) and females (55.4%). One or more comorbid illnesses were noted in 98.3% of the patients who died, and in 72.3% of cases, they were the primary cause of death. Bleeding was the primary cause of death in 18.6% of patients. Upper endoscopy was performed in 68.8% of cases, therapeutic endoscopy in 12.6%, repeat endoscopy in 10.7%, and surgery in 4.4%. Blood transfusions were administered in 47.3% of cases, with most patients receiving < 5 units of blood. Rebleeding after initial hemostasis was noted in 7.1% of cases. Factors related to increased mortality include age > 60 (p < 0.001), transfusion requirement > 5 U (p < 0.001), presence of comorbid illness (p < 0.001), rebleeding after initial hemostasis (p < 0.005), surgery (p < 0.001), and UGIB occurring during hospitalization (p = 0.027).
CONCLUSIONS: We conclude: 1) The incidence of UGIB is 2-fold greater in males than in females, in all age groups; however, the death rate is similar in both sexes. 2) The mortality rate in this study is slightly lower than in most previous studies and may be more reflective of the average mortality in the community at large. 3) In UGIB patients, comorbid illness and not actual bleeding is the major cause of death. 4) Upper endoscopy was performed less often in this study than in other studies, and there were fewer blood transfusions; however, rebleeding and mortality rates remained similar.
METHODS: A retrospective chart review of Department of Defense military medical treatment facilities for UGIB was performed from October 1990 through September 1991. Core data such as demographic information were analyzed, as well as specific data relating to UGIB.
RESULTS: The incidence of UGIB was 36 per 100,000 population with a male-to-female ratio of 2.18 and a mean age of 52 +/- 19.65 yr. The number of cases increased with age; 44.5% of all patients were > or = 60 yr old. The overall mortality was 7.0% (231 of 3294), and death rates were similar among males and females (7.1% vs. 6.8%) with an odds ratio of 1.03 (CI: 0.77-1.402). Mortality increased with age in both genders; 73.2% of deaths occurred in patients more than 60 yr old. Comorbid illness was noted in 50.9% (1675 of 3294) of patients, with similar occurrence in males (48.7%) and females (55.4%). One or more comorbid illnesses were noted in 98.3% of the patients who died, and in 72.3% of cases, they were the primary cause of death. Bleeding was the primary cause of death in 18.6% of patients. Upper endoscopy was performed in 68.8% of cases, therapeutic endoscopy in 12.6%, repeat endoscopy in 10.7%, and surgery in 4.4%. Blood transfusions were administered in 47.3% of cases, with most patients receiving < 5 units of blood. Rebleeding after initial hemostasis was noted in 7.1% of cases. Factors related to increased mortality include age > 60 (p < 0.001), transfusion requirement > 5 U (p < 0.001), presence of comorbid illness (p < 0.001), rebleeding after initial hemostasis (p < 0.005), surgery (p < 0.001), and UGIB occurring during hospitalization (p = 0.027).
CONCLUSIONS: We conclude: 1) The incidence of UGIB is 2-fold greater in males than in females, in all age groups; however, the death rate is similar in both sexes. 2) The mortality rate in this study is slightly lower than in most previous studies and may be more reflective of the average mortality in the community at large. 3) In UGIB patients, comorbid illness and not actual bleeding is the major cause of death. 4) Upper endoscopy was performed less often in this study than in other studies, and there were fewer blood transfusions; however, rebleeding and mortality rates remained similar.
Full text links
Trending Papers
Management of type 2 diabetes in the new era.Hormones : International Journal of Endocrinology and Metabolism 2023 September 14
Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it.Acute and critical care. 2023 August
The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation.Journal of Intensive Care 2023 May 24
Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.JACC. Heart Failure 2023 August 26
Hypertensive Heart Failure.Journal of Clinical Medicine 2023 August 3
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain.Journal of Cardiovascular Development and Disease 2023 July 31
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app